关键词: 抑郁症, 舒肝解郁胶囊, 艾司西酞普兰, 随机对照试验, Meta分析

Abstract: Objective: To systemically evaluate shugan jieyu capsule combined with escitalopram efficacy and safety in the treatment of depression,and to provide reference for guiding its clinical application.Methods: Databases, including CNKI, WanFang, VIP and PubMed Data, were retrieved by two assessors independently so as to retrieve randomized controlled trials(RCTs)on Shugan Jieyu Capsule combined with escitalopram in treating depression.Data were extracted according to inclusion and exclusion criteria, and RevMan 5.3 software was used for quality evaluation and meta analysis of the included literature. Results: A total of 836 subjects were included in 10 RCTs. Meta analysis results showed that the experimental group (Shugan Jieyu Capsule combined with escitalopram) had better clinical efficacy, and the total response rate [OR=3.15,95%CI(2.08,4.79),P<0.000 01] was statistically significant compared with the control group (escitalopram alone). In trems of HAMD score before and after treatment, [MD=-3.03,95%CI(-4.59,-1.47),P=0.000 1], the difference was statistically significant.Results of adverse reaction incidence[OR=0.74,95%CI(0.50,1.08),P=0.12] showed that the difference was not statistically significant.Conclusion: Shugan Jieyu Capsule combined with escitalopram has a good effect in the treatment of depression, and can significantly reduce patients' HAMD score, which has a good application prospect.

Key words: depression, Shuganjieyu Capsule, escitalopram, randomized controlled trials, Meta analysis